Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 2, 2000, Pages 114-118

  Nakamura, Yoichi ^a   Sekine, Ikuo ^a   Furuse, Kiyoyuki ^b   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

Chemotherapy; Elderly; Non small cell lung cancer; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

AGED; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG INFUSION; FEMALE; GERIATRIC PATIENT; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033899190     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000143     Document Type: Article

References (28)

1. Cancer chemotherapy in the elderly
2. Promotion of microtuble assembly in vitro by taxol
3. Phase II study of Taxol, merbarone and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results
4. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer
5. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer
6. Phase II study of 3-hour infusion of paclitaxel in patients in previously untreated non-small-cell lung cancer
7. Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small-cell lung cancer
8. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
9. Cancer pharmacology in the elderly
10. Studies on structure and function of bone marrow. II. Variations in cellularity in various bones with advancing years of life and their relative response to stimuli
11. Normal variations with aging on the amount of hematopoietic tissue in bone marrow front the anterior iliac crest
12. Normal age-related patterns of cellular and fatty bone marrow distribution in the axial skeleton: MR imaging study
13. Variability in human cytochrome P450 paclitaxel metabolism
14. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: A European Cancer Centre (ECC) trial
15. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
16. Response
17. Influence of liver disease and environmental factors on hepatic monooxygenase activity in vitro
18. The effect of age on pathways of drug metabolism in human liver
19. Drug disposition in old age
20. Effects of aging on antipyrine clearance: Predictive factors of metabolizing capacity
21. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience
22. Treatment outcome in Hodgkin's disease in patients above the age of 60: A population-based study
23. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia
24. Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: Significance of expression of the multidrug resistance gene-1 (MDR 1)
25. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study
26. The neurotoxicity of high-dose cytosine arabinoside is age-related
27. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group